| Abstract |
Objective To study the clinical efficacy and safety of mianserin and milnacipran in the treatment of depression. Methods Ninety-six patients with depression admitted to our hospital from February 2016 to February 2019 were selected as subjects. They were randomly divided into the two groups. Patients in the control group were treated with mianserin, and patients in the observation group were treated with milnacipran for 3 months. Before and after treatment, the Hamilton depression scale (HAMD), social function scale (SFRS), Pittsburgh sleep quality score (PSQI), and Hamilton anxiety scale (HAMA) were used to evaluate depression, social function, sleep quality, and anxiety. The incidence of adverse reactions during treatment was evaluated and the overall efficacy was evaluated. Results There was no significant difference in the total effective rate between the two groups (P>0.05). The HAMD, PSQI score and HAMA score were significantly lower after treatment, and the SFRS score was significantly higher (P<0.05). There was no significant difference between the two groups after treatment (P>0.05). There was no significant difference in the incidence of gastrointestinal reactions, headache/dizziness, liver dysfunction and loss of appetite between the two groups (P>0.05). The incidence of dysfunction and urinary insufficiency was significantly higher than that of the control group, and the difference was statistically significant (P<0.05). Conclusion Both mianserin and milnacipran can effectively improve anxiety and depression in patients with depression, improve sleep quality and social function, but milnacipran may cause side effects such as sexual dysfunction and urinary incontinence. Clinical application requires careful use, dosage and medication according to the patients specific conditions.
|